Suboxone Tooth Decay Litigation Advances Amid Record Access Challenges

The Suboxone tooth decay litigation, a significant legal challenge against Indivior, the manufacturer of Suboxone, is making notable progress as of July 2025. This multidistrict litigation (MDL) is rooted in compelling scientific evidence that connects sublingual Suboxone strips to severe dental problems, offering hope to those affected seeking redress. A major obstacle in the litigation has been the delay in obtaining pharmacy records, crucial for verifying Suboxone usage. Walgreens faces legal scrutiny for reportedly not complying with court orders to produce these records promptly, while other entities such as Safeway and Porch Light Health have adhered to the requests.

Adjustments to the plaintiff pool have been made, with 48 individuals out of an initial 500 being excluded from early-stage discovery due to voluntary dismissals or documentation discrepancies. These spots have been filled through a random selection process, streamlining the pool for the bellwether trial phase. This refinement ensures that the remaining 100 cases, with four earmarked for trial, are strong and well-documented.

Despite the increasing number of individuals coming forward with claims, a settlement does not appear imminent. Legal experts speculate that Indivior might be postponing negotiations to wait out the three-year statute of limitations, which could limit their liability to new claims. Substantive settlement talks are now anticipated to occur in late 2025 or early 2026. For those suffering from Suboxone-induced dental injuries, staying updated on the litigation's progress is essential. Resources like Lawsuit Legal News provide valuable updates and guidance, helping victims understand their rights and the legal process.